The Latest Analyst Ratings for aTyr Pharma
Portfolio Pulse from Benzinga Insights
In the last 3 months, 7 analysts have offered 12-month price targets for aTyr Pharma (NASDAQ:LIFE), with an average price target of $21.29, up 46.83% from the previous average of $14.50. The company has received 3 bullish and 4 somewhat bullish ratings.
May 23, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
aTyr Pharma's average 12-month price target has increased by 46.83% to $21.29, with 3 bullish and 4 somewhat bullish ratings from 7 analysts in the last 3 months.
The increase in the average 12-month price target for aTyr Pharma indicates a positive outlook from analysts. With 3 bullish and 4 somewhat bullish ratings, the overall sentiment is positive, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100